Načítá se...
Hidden Targets in RAF Signalling Pathways to Block Oncogenic RAS Signalling
Oncogenic RAS (Rat sarcoma) mutations drive more than half of human cancers, and RAS inhibition is the holy grail of oncology. Thirty years of relentless efforts and harsh disappointments have taught us about the intricacies of oncogenic RAS signalling that allow us to now get a pharmacological grip...
Uloženo v:
| Vydáno v: | Genes (Basel) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8070103/ https://ncbi.nlm.nih.gov/pubmed/33920182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/genes12040553 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|